falsefalse

My Treatment Approach: Navigating First-Line Treatment Options in Locally Advanced and Metastatic Urothelial Cancer - Episode 6

Final Clinical Perspectives: EV+P is the New Standard of Care in Frontline Treatment of UC

Thomas Powles, MBBS, MRCP, MD, discusses how according to the ESMO guidelines, enfortumab vedotin plus pembrolizumab (EV+P) has become the new standard of first-line therapy in advanced urothelial carcinoma, and if there are patients who are ineligible for EV+P, alternatives are available such as nivolumab plus cisplatin/gemcitabine or platinum-based chemotherapy followed by maintenance avelumab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
    EP. 2: Single-Agent Immune Therapy in UC: The Need for More
    EP. 3: KEYNOTE-361 Highlights: Challenges and Insights
    EP. 4: Challenges With Avelumab Maintenance in Bladder Cancer and Introduction to ADCs in UC
    EP. 5: Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy
    Now Viewing
    EP. 6: Final Clinical Perspectives: EV+P is the New Standard of Care in Frontline Treatment of UC

    Related Content:

    My Treatment Approach: Navigating First-Line Treatment Options in Locally Advanced and Metastatic Urothelial CancerVideo SeriesClinicalInsightsUrothelial Cancer
    Clinical Insights on the Next Treatment Approach for Metastatic HER2+  Breast Cancer with Brain Metastasis
    EBMT 2025 Spotlight: Long-Term Outcomes With PTCy – Insights From the ALWP-EBMT
    Evolving Targeted Therapy Approaches in Resectable Early-Stage NSCLC With Actionable Mutations
    x